Zobrazeno 1 - 10
of 319
pro vyhledávání: '"Charles Geyer"'
Publikováno v:
The Military Engineer, 1958 May 01. 50(335), 242-242.
Externí odkaz:
https://www.jstor.org/stable/44577274
Publikováno v:
Journal (American Water Works Association), 1954 Nov 01. 46(11), 52-52.
Externí odkaz:
https://www.jstor.org/stable/41253585
Autor:
Dallman, Elizabeth
Publikováno v:
Instrumentalist; Nov2001, Vol. 56 Issue 4, p13-17, 5p
Autor:
Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge
Publikováno v:
Cancer Research. 83:GS1-05
Background: Late recurrence of breast cancer after 5 years accounts for about 50% of recurrences in hormone receptor (HR)-positive early breast cancer (EBC). TAILORx established non-inferiority of adjuvant endocrine therapy (ET) given for at least 5
Autor:
McKee, J. E.
Publikováno v:
Science, 1958 Sep 01. 128(3324), 589-590.
Externí odkaz:
https://www.jstor.org/stable/1754732
Autor:
Buswell, A. M.
Publikováno v:
Science, 1955 Apr 01. 121(3145), 502-503.
Externí odkaz:
https://www.jstor.org/stable/1681889
Autor:
Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer, Andrew Tutt
Publikováno v:
Breast Cancer.
Background The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and contextualized with reference to the global OlympiA population. Methods Patient
Autor:
José Baselga, Neal Rosen, Joaquin Arribas, David Cameron, Charles Geyer, Henry Gomez, Maria Koehler, Robert Gagnon, Catherine Ellis, Josep Lluis Parra, Marta Guzman, Gertrudis Sánchez, Pier Davide Angelini, José Jimenez, Claudia Aura, Ludmila Prudkin, Sarat Chandarlapaty, Maurizio Scaltriti
Supplementary Data from Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ab4055c3c0afbef48f7ad680292f73
https://doi.org/10.1158/1078-0432.22442855.v1
https://doi.org/10.1158/1078-0432.22442855.v1
Autor:
José Baselga, Neal Rosen, Joaquin Arribas, David Cameron, Charles Geyer, Henry Gomez, Maria Koehler, Robert Gagnon, Catherine Ellis, Josep Lluis Parra, Marta Guzman, Gertrudis Sánchez, Pier Davide Angelini, José Jimenez, Claudia Aura, Ludmila Prudkin, Sarat Chandarlapaty, Maurizio Scaltriti
Purpose: A subgroup of human epidermal growth factor receptor 2 (HER2)–overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a837f5e32a513948c40bba407b6363d6
https://doi.org/10.1158/1078-0432.c.6519506
https://doi.org/10.1158/1078-0432.c.6519506
Autor:
Renn, Charles E.
Publikováno v:
The Quarterly Review of Biology, 1955 Dec 01. 30(4), 417-417.
Externí odkaz:
https://www.jstor.org/stable/2814282